South Korean biotech developer SK Biopharmaceuticals has signed a supply agreement with Eckert & Ziegler in which Eckert & Ziegler will provide actinium-225 (Ac-225) to accelerate R & D activities for radiopharmaceutical surgical therapies.
SK Biopharmaceuticals specializes in research, development, and commercialization of treatments for central nervous system disorders. The company’s development pipeline includes SKL35501, an innovative radiopharmaceutical labeled with Ac-225 with potential in the treatment of multiple types of cancer, including colorectal, breast, pancreatic, and head and neck cancers.
By securing a reliable supply of the alpha-emitting radioisotope from Eckert & Ziegler, SK Biopharmaceuticals will be able to move this and other programs forward, the firms said.
